2017
Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer
Abstract: TPF is a suitable option for Asian patients with borderline resectable or unresectable HNSCC who are scheduled for ICT.
Search citation statements
Paper Sections
Select...
18
8
7
4
Citation Types
2
27
2
0
Year Published
2017
2025
Publication Types
Select...
29
4
2
Relationship
6
29
Authors
Journals
Cited by 33 publications
(31 citation statements)
References 30 publications
2
27
2
0
“…In comparison, the incidence of Grade 3─4 neutropenia for patients receiving standard and high‐dose TPF in TAX323 and TAX324 was substantially higher than in the present study, at 83% and 76.9%, respectively. (Lorch et al, ; Posner et al, ; Vermorken et al, ) However, the rates of Grade 3─4 neutropenia in this study were consistent with those reported in other studies of dose‐modified TPF (35.0%─46.7%; Huang et al, ; Wang et al, ).…”
Section: Discussionsupporting
confidence: 91%
“…In comparison, the incidence of Grade 3─4 neutropenia for patients receiving standard and high‐dose TPF in TAX323 and TAX324 was substantially higher than in the present study, at 83% and 76.9%, respectively. (Lorch et al, ; Posner et al, ; Vermorken et al, ) However, the rates of Grade 3─4 neutropenia in this study were consistent with those reported in other studies of dose‐modified TPF (35.0%─46.7%; Huang et al, ; Wang et al, ).…”
Section: Discussionsupporting
confidence: 91%
“…In contrast, another Taiwanese, single-arm study using a TPF 90 -modified dosing regimen reported a median PFS of 16 months which is longer than the present study. (Wang et al, 2017) However, OS was lower in this previous study versus the present study (21 months).…”
Section: Discussioncontrasting
confidence: 74%
“…A phase III study including 157 patients does not show any signi cant difference between radiochemotherapy and induction, followed by chemoradiotherapy [26], which was supported by our data. Wang et al [27] reported a median progression-free survival (PFS) of 16 months, which was shorter than that reported in the present study. However, the OS was lower in this previous study compared with that in the present study (23.20 months).…”
Section: Discussioncontrasting
confidence: 80%
“…This increase in the cytotoxic result can be used to reduce the typical doses of CIS used for treatment in try, to reduce dosedependent side effects. Our results were comparable to those obtained using SFNN alongside other forms of tumors such as gastric carcinoma, pancreas, prostate cancers, head and neck cancers (27,29) . The findings of this study have shown that a combination of SFN and CIS is an efficient in vitro way of achieving synergistic anti-tumor effects against OSCC.…”
Section: Tongue Cancer Was the Cell Line Of Choice Insupporting
confidence: 83%
